There are currently two guideline-recommended diagnostic criteria in use to define a periprocedural myocardial infarction (PPMI) following coronary artery bypass grafting (CABG): the 4th Universal Definition of Myocardial Infarction (UDMI) and the Society of Cardiovascular Angiography and Interventions (SCAI).

Kendra Grubb | Surgical Director of Structural Heart and Valve Center and Associate Professor of Cardiovascular Surgery at the Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA

European and American experts recommend physiology-guided myocardial revascularisation.1,2,3 Nevertheless, physiology-guided revascularisation does not exceed 10% in the best scenario, worldwide.

Treating chronic total occlusions (CTO) by the antegrade approach requires appropriate devices and skill in resource-limited settings. Good guide-catheter support is crucial.1,2 Patients with diabetes and narrower radial arteries are prone to spasm with larger guiding catheters, and may benefit from a slender approach to percutaneous coronary intervention (PCI).

The aim of the panel was to understand how to adapt treatment strategy to the underlying anatomy in a case of left main bifurcation percutaneous coronary intervention.

Even surgeons are not unanimous when offering such a solution: ligation of the saphenofemoral junction (SFJ), stripping of the varicose veins, and resection of the greater saphenous vein (GSV)

The focus of the EuroPCR 2021 ‘Structural Theatre’ session, compared LAAC and direct oral anticoagulant (DOAC) treatment avenues for stroke prevention.

Percutaneous treatment of chronic total occlusion (CTO) is considered one of the most challenging procedures due to the high incidence of complications and the relatively low success rate compared with non-CTO percutaneous coronary interventions (PCI).

Bioresorbable vascular scaffolds (BRS) are a new and promising technology. BRS have been developed to provide the same advantages as drug-eluting stents, including radial strength, prevention of vessel recoil, and release of an antiproliferative drug.

Today, coronary flow reserve (CFR) is used to evaluate the microcirculation, but not the haemodynamic significance, of coronary stenosis. Fractional flow reserve (FFR) is the gold standard for this purpose, with a cut-off value of 0.8 for intervention. Its simplicity, however, limits its predictive value.